anticoagulants, oral factor Xa inhibitors, rivaroxaban
DISEASE INTERVENTION COMPARISON RESULTS
N Engl J Med. 2011 Sep 8;365(10):883-91. Epub 2011 Aug 10 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban, 20 mg once daily
As Treatment, Chronic
Is equal Than
dose-adjusted warfarin
To reduce stroke or systemic embolism (2.1% per year rivaroxaban VS 2.4% warfarin), or cause clinically relevant bleeding, major or nonmajor (15% per year both)
Circulation. 2014 Jul 8;130(2):138-46 Randomized Controlled Trial, Multicenter Study
IN atrial fibrillation, non valvular, stroke, ischemic, cerebral infarction, embolic, older patients The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban
As Treatment, Chronic
Is equal Than
vitamine K antagonists, warfarin
To modify, in patients > 75 years, stroke (2.29% rivaroxaban VS 2.85% warfarin per 100 patient-years) or major bleeding (4.86% rivaroxaban versus 4.40% warfarin per 100 patient-years). Older patients had more strokes and major bleedings than young ones
N Engl J Med. 2012 Jan 5;366(1):9-19. Epub 2011 Nov 13 Randomized Controlled Trial, Multicenter Study
IN coronary disease, acute coronary syndrome The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban, 2.5 or 5 mg twice daily, in addition to double antiplatelet treatment
As Treatment, Chronic
Is better Than
placebo
To reduce at 13 months cardiovascular events (cardiovascular death, myocardial infartion , stroke): 8.9% rivaroxaban VS 10.7% placebo. However, it increases major bleedings: 2.1% rivaroxaban VS 0.6% placebo
N Engl J Med. 2017 10 05;377(14):1319-1330 Randomized Controlled Trial, Multicenter Study
IN coronary disease, stable The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily)
As Treatment, Chronic
Is better Than
rivaroxaban (5 mg twice daily) alone, or aspirin (100 mg once daily) alone
To reduce cardiovascular events (death, stroke or MI): 4.1% riva+aspirine VS 5.4% aspirine. But increased major bleeding: 3.1% VS 1.9%. Riva 5 mg/d alone did not better than aspirin and had more bleeding.
N Engl J Med. 2018 06 07;378(23):2191-2201 Randomized Controlled Trial, Multicenter Study
IN stroke, ischemic, cerebral infarction, embolic, undetermined source The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban, 15 mg/d
As Treatment, Chronic
Is worse Than
aspirin 100 mg/d
To reduce at 11 months recurrent (ischemic or hemorrhagic) stroke (5% both Tts) while increasing major bleeding (2% rivarox VS 1% aspirin)
N Engl J Med. 2010 Dec 23;363(26):2499-510 Randomized Controlled Trial, Multicenter Study
IN thromboembolic disease, deep venous thrombosis The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban, 15 mg twice daily for 3 weeks, followed by 20 mg once daily
As Treatment, Acute
Is equal Than
acute LMWH (enoxaparin) followed by a vitamin K antagonist
To modify recurrent venous thromboembolism (2.1% rivaroxaban VS 3% enoxaparin plus warfarin) or clinically ssignificant bleeding (8% both groups)
N Engl J Med. 2012 Apr 5;366(14):1287-97 Randomized Controlled Trial, Multicenter Study
IN thromboembolic disease, pulmonary embolism The Use of
anticoagulants, oral factor Xa inhibitors, rivaroxaban, 15 mg twice daily for 3 weeks, followed by 20 mg once daily
As Treatment, Acute
Is equal Than
acute heparins LMWH (enoxaparin) followed by a vitamin K antagonist
To reduce recurrence of thromboembolic events at 6 -12 months (2,1% rivarox VS 2,8% warfarin) while not increasing clinically significant bleeding (10% rivarox VS 11% warfarin)